Free Trial
NASDAQ:TBIO

Telesis Bio (TBIO) Stock Price, News & Analysis

Telesis Bio logo
$1.37
+0.01 (+0.74%)
(As of 11/1/2024 ET)

About Telesis Bio Stock (NASDAQ:TBIO)

Key Stats

Today's Range
$1.30
$1.37
50-Day Range
$1.35
$4.07
52-Week Range
$1.27
$15.46
Volume
8,092 shs
Average Volume
478,404 shs
Market Capitalization
$2.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Receive TBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Telesis Bio and its competitors with MarketBeat's FREE daily newsletter.

TBIO Stock News Headlines

Telesis Bio Announces Departure of Chief Legal Officer
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
See More Headlines

TBIO Stock Analysis - Frequently Asked Questions

Telesis Bio's stock was trading at $7.1820 at the beginning of the year. Since then, TBIO stock has decreased by 80.9% and is now trading at $1.37.
View the best growth stocks for 2024 here
.

Telesis Bio, Inc. (NASDAQ:TBIO) announced its earnings results on Wednesday, August, 7th. The company reported ($7.03) EPS for the quarter. The business had revenue of $1.55 million for the quarter, compared to analyst estimates of $6.50 million. Telesis Bio had a negative trailing twelve-month return on equity of 359.32% and a negative net margin of 282.58%.

Shares of Telesis Bio reverse split on Thursday, May 9th 2024. The 1-18 reverse split was announced on Thursday, May 9th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

Telesis Bio (TBIO) raised $100 million in an initial public offering on Thursday, June 28th 2018. The company issued 7,700,000 shares at a price of $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI served as the underwriters for the IPO.

Shares of TBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Telesis Bio investors own include Ford Motor (F), Pfizer (PFE), Palantir Technologies (PLTR), PayPal (PYPL), SoFi Technologies (SOFI), Plug Power (PLUG) and XPeng (XPEV).

Company Calendar

Last Earnings
8/07/2024
Today
11/02/2024
Next Earnings (Estimated)
11/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:TBIO
Previous Symbol
NASDAQ:DNAY
Fax
N/A
Employees
200
Year Founded
N/A

Profitability

Net Income
$-47,720,000.00
Net Margins
-282.58%
Pretax Margin
-279.62%

Debt

Sales & Book Value

Annual Sales
$27.51 million
Book Value
$0.14 per share

Miscellaneous

Free Float
1,339,000
Market Cap
$2.42 million
Optionable
Optionable
Beta
1.75
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:TBIO) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners